Tue September 10, 2019
Reducing the Global Burden of Dementia: The First Effective Treatment for Alzheimer’s Disease
SEE EVENT DETAILS
Dale Bredesen, M.D., Founding President and CEO, Buck Institute for Research on Aging; Director of the Easton Center for Alzheimer’s Disease Research, UCLA
Everyone knows someone who’s survived cancer. But no one knows anyone who’s survived Alzheimer’s—until now. Alzheimer’s disease is a global pandemic and the third leading cause of death in the United States. Of the 326 million Americans currently living, approximately 45 million will develop Alzheimer's disease during their lifetimes unless effective prevention programs are instituted. The 99 percent failure rate of Alzheimer’s drug trials underscores both the area of greatest biomedical failure and the need for a more complete understanding of the drivers (i.e., the root causes) of the disease. Despite these alarming statistics, it has now been demonstrated that early stage Alzheimer's and its precursors, mild cognitive impairment (MCI) and subjective cognitive impairment (SCI), can be prevented and in some cases reversed.
Join Dale Bredesen as he presents a novel programmatic approach that identifies and targets the multiple contributors to cognitive decline. Based on his findings from over 30 years of research into the mechanisms of neurodegenerative diseases, this approach led to the first published reports of the reversal of cognitive decline. Currently, over 3,000 patients use the protocol described in these initial reports, with success that has not been described previously.
Location: 110 The Embarcadero, Toni Rembe Rock Auditorium, San Francisco Time: 5:30 p.m check-in, 6 p.m. program MLF: Health & Medicine Program Organizer: Adrea Brier
All ticket sales are final and nonrefundable.
show less
Everyone knows someone who’s survived cancer. But no one knows anyone who’s survived Alzheimer’s—until now. Alzheimer’s disease is a global pandemic and the third leading cause of death in the United States. Of the 326 million Americans currently living, approximately 45 million will develop Alzheimer's disease during their lifetimes unless effective prevention programs are instituted. The 99 percent failure rate of Alzheimer’s drug trials underscores both the area of greatest biomedical failure and the need for a more complete understanding of the drivers (i.e., the root causes) of the disease. Despite these alarming statistics, it has now been demonstrated that early stage Alzheimer's and its precursors, mild cognitive impairment (MCI) and subjective cognitive impairment (SCI), can be prevented and in some cases reversed.
Join Dale Bredesen as he presents a novel programmatic approach that identifies and targets the multiple contributors to cognitive decline. Based on his findings from over 30 years of research into the mechanisms of neurodegenerative diseases, this approach led to the first published reports of the reversal of cognitive decline. Currently, over 3,000 patients use the protocol described in these initial reports, with success that has not been described previously.
Location: 110 The Embarcadero, Toni Rembe Rock Auditorium, San Francisco Time: 5:30 p.m check-in, 6 p.m. program MLF: Health & Medicine Program Organizer: Adrea Brier
All ticket sales are final and nonrefundable.
Dale Bredesen, M.D., Founding President and CEO, Buck Institute for Research on Aging; Director of the Easton Center for Alzheimer’s Disease Research, UCLA
Everyone knows someone who’s survived cancer. But no one knows anyone who’s survived Alzheimer’s—until now. Alzheimer’s disease is a global pandemic and the third leading cause of death in the United States. Of the 326 million Americans currently living, approximately 45 million will develop Alzheimer's disease during their lifetimes unless effective prevention programs are instituted. The 99 percent failure rate of Alzheimer’s drug trials underscores both the area of greatest biomedical failure and the need for a more complete understanding of the drivers (i.e., the root causes) of the disease. Despite these alarming statistics, it has now been demonstrated that early stage Alzheimer's and its precursors, mild cognitive impairment (MCI) and subjective cognitive impairment (SCI), can be prevented and in some cases reversed.
Join Dale Bredesen as he presents a novel programmatic approach that identifies and targets the multiple contributors to cognitive decline. Based on his findings from over 30 years of research into the mechanisms of neurodegenerative diseases, this approach led to the first published reports of the reversal of cognitive decline. Currently, over 3,000 patients use the protocol described in these initial reports, with success that has not been described previously.
Location: 110 The Embarcadero, Toni Rembe Rock Auditorium, San Francisco Time: 5:30 p.m check-in, 6 p.m. program MLF: Health & Medicine Program Organizer: Adrea Brier
All ticket sales are final and nonrefundable.
read more
Everyone knows someone who’s survived cancer. But no one knows anyone who’s survived Alzheimer’s—until now. Alzheimer’s disease is a global pandemic and the third leading cause of death in the United States. Of the 326 million Americans currently living, approximately 45 million will develop Alzheimer's disease during their lifetimes unless effective prevention programs are instituted. The 99 percent failure rate of Alzheimer’s drug trials underscores both the area of greatest biomedical failure and the need for a more complete understanding of the drivers (i.e., the root causes) of the disease. Despite these alarming statistics, it has now been demonstrated that early stage Alzheimer's and its precursors, mild cognitive impairment (MCI) and subjective cognitive impairment (SCI), can be prevented and in some cases reversed.
Join Dale Bredesen as he presents a novel programmatic approach that identifies and targets the multiple contributors to cognitive decline. Based on his findings from over 30 years of research into the mechanisms of neurodegenerative diseases, this approach led to the first published reports of the reversal of cognitive decline. Currently, over 3,000 patients use the protocol described in these initial reports, with success that has not been described previously.
Location: 110 The Embarcadero, Toni Rembe Rock Auditorium, San Francisco Time: 5:30 p.m check-in, 6 p.m. program MLF: Health & Medicine Program Organizer: Adrea Brier
All ticket sales are final and nonrefundable.
show less
Date/Times:
110 The Embarcadero, San Francisco, CA 94105
The Best Events
Every Week in Your Inbox
From Our Sponsors
UPCOMING EVENTS
Great suggestion! We'll be in touch.
Event reviewed successfully.